APELLIS PHARMACTDL Current Ratio vs. Return On Asset

1JK Stock  EUR 31.22  0.02  0.06%   
Taking into consideration APELLIS PHARMACTDL's profitability measurements, APELLIS PHARMACTDL 0001 may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess APELLIS PHARMACTDL's ability to earn profits and add value for shareholders.
For APELLIS PHARMACTDL profitability analysis, we use financial ratios and fundamental drivers that measure the ability of APELLIS PHARMACTDL to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well APELLIS PHARMACTDL 0001 utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between APELLIS PHARMACTDL's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of APELLIS PHARMACTDL 0001 over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between APELLIS PHARMACTDL's value and its price as these two are different measures arrived at by different means. Investors typically determine if APELLIS PHARMACTDL is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, APELLIS PHARMACTDL's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

APELLIS PHARMACTDL 0001 Return On Asset vs. Current Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining APELLIS PHARMACTDL's current stock value. Our valuation model uses many indicators to compare APELLIS PHARMACTDL value to that of its competitors to determine the firm's financial worth.
APELLIS PHARMACTDL 0001 is number one stock in current ratio category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the APELLIS PHARMACTDL's earnings, one of the primary drivers of an investment's value.

APELLIS Return On Asset vs. Current Ratio

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

APELLIS PHARMACTDL

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
4.15 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

APELLIS PHARMACTDL

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.46
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

APELLIS Return On Asset Comparison

APELLIS PHARMACTDL is currently under evaluation in return on asset category among its peers.

APELLIS PHARMACTDL Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in APELLIS PHARMACTDL, profitability is also one of the essential criteria for including it into their portfolios because, without profit, APELLIS PHARMACTDL will eventually generate negative long term returns. The profitability progress is the general direction of APELLIS PHARMACTDL's change in net profit over the period of time. It can combine multiple indicators of APELLIS PHARMACTDL, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts. APELLIS PHARMACT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 445 people.

APELLIS Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on APELLIS PHARMACTDL. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of APELLIS PHARMACTDL position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the APELLIS PHARMACTDL's important profitability drivers and their relationship over time.

Use APELLIS PHARMACTDL in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if APELLIS PHARMACTDL position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in APELLIS PHARMACTDL will appreciate offsetting losses from the drop in the long position's value.

APELLIS PHARMACTDL Pair Trading

APELLIS PHARMACTDL 0001 Pair Trading Analysis

The ability to find closely correlated positions to APELLIS PHARMACTDL could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace APELLIS PHARMACTDL when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back APELLIS PHARMACTDL - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling APELLIS PHARMACTDL 0001 to buy it.
The correlation of APELLIS PHARMACTDL is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as APELLIS PHARMACTDL moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if APELLIS PHARMACTDL 0001 moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for APELLIS PHARMACTDL can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your APELLIS PHARMACTDL position

In addition to having APELLIS PHARMACTDL in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Communication Thematic Idea Now

Communication
Communication Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Communication theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Communication Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in APELLIS Stock

To fully project APELLIS PHARMACTDL's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of APELLIS PHARMACTDL 0001 at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include APELLIS PHARMACTDL's income statement, its balance sheet, and the statement of cash flows.
Potential APELLIS PHARMACTDL investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although APELLIS PHARMACTDL investors may work on each financial statement separately, they are all related. The changes in APELLIS PHARMACTDL's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on APELLIS PHARMACTDL's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.